menu

On The Clinic floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management

10 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease. Though such advancements are welcome, they continue to raise new questions about how to optimize management for individual patients. In this program, real clinicians who treat MS pose their most pressing clinical questions to an expert panel. These specialists then provide their best answers through literature and their own clinical experience.

  • Disclosure of Conflicts of Interest

    DR. SHIN REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS.

    Consulting Fees: Alexion Pharmaceuticals, BMS, EMD Serono, Genentech, Horizon Therapeutics, Icometric, and Novartis
    Speakers' Bureau: Alexion Pharmaceuticals, BMS, EMD Serono, Genentech, Horizon Therapeutics, Novartis, and Sanofi-Genzyme

    DR. ALVAREZ REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS.

    Consulting Fees: Alexion, Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Horizon, Motric Bio, Novartis, Sanofi, Scionic, and TG Therapeutics
    Grants/Research Support: Atara, Biogen, Genentech/Roche, Novartis, TG Therapeutics, Patient-Centered Outcomes Research Initiative, National Multiple Sclerosis Society, National Institutes of Health, and Rocky Mountain MS Center

    DR. OH REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS.

    Consulting Fees: Biogen-Idec, EMD Serono, Horizon Therapeutics, Eli-Lilly, Novartis, Roche, and Sanofi-Genzyme
    Grants/Research Support: Biogen-Idec and Roche

  • Target Audience

    This activity is intended for general neurologists, neurodegenerative disease specialists, and other healthcare professionals involved in the diagnosis and management of patients with MS.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Apply evolving diagnostic considerations (e.g., oligoclonal bands, autoantibodies, rising biomarkers) in appropriate situations to optimize timely recognition of MS presentations
    • Evaluate key clinical and patient-specific factors that may influence DMT selection to optimally match each patient with particular therapeutic strategies
    • Discuss strategies for the identification and response to subacute disease changes to develop evidence-based management plans for patients
    • Utilize important long-term considerations in MS patient care to tailor clinical decisions commensurate with individual patient needs
  • Accreditation and Credit Designation Statements

    This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient, LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

    PHYSICIAN CREDIT
    Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
    A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

  • Disclaimer

    Disclosure of Relevant Financial Relationships

    To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

    All relevant conflicts of interest have been mitigated prior to the start of the activity.
    None of the planners, reviewers, Efficient LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

    Disclosure of Unlabeled Use/Disclaimer
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Method of Participation
    There are no fees for participating in and receiving credit for this activity. During the period April 25, 2024 through April 25, 2025, participants must: 1) read the learning objectives and faculty disclosures, 2) complete the pre-activity assessment, 3) study the educational activity, 4) complete the posttest by recording the best answer to each question, and 5) complete the evaluation form.

    Media
    Internet

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.

  • Commercial Support

    This activity is supported by an educational grant from Bristol Myers Squibb and Novartis Pharmaceuticals.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease. Though such advancements are welcome, they continue to raise new questions about how to optimize management for individual patients. In this program, real clinicians who treat MS pose their most pressing clinical questions to an expert panel. These specialists then provide their best answers through literature and their own clinical experience.

  • Disclosure of Conflicts of Interest

    DR. SHIN REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS.

    Consulting Fees: Alexion Pharmaceuticals, BMS, EMD Serono, Genentech, Horizon Therapeutics, Icometric, and Novartis
    Speakers' Bureau: Alexion Pharmaceuticals, BMS, EMD Serono, Genentech, Horizon Therapeutics, Novartis, and Sanofi-Genzyme

    DR. ALVAREZ REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS.

    Consulting Fees: Alexion, Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Horizon, Motric Bio, Novartis, Sanofi, Scionic, and TG Therapeutics
    Grants/Research Support: Atara, Biogen, Genentech/Roche, Novartis, TG Therapeutics, Patient-Centered Outcomes Research Initiative, National Multiple Sclerosis Society, National Institutes of Health, and Rocky Mountain MS Center

    DR. OH REPORTED THE FOLLOWING FINANCIAL RELATIONSHIPS.

    Consulting Fees: Biogen-Idec, EMD Serono, Horizon Therapeutics, Eli-Lilly, Novartis, Roche, and Sanofi-Genzyme
    Grants/Research Support: Biogen-Idec and Roche

  • Target Audience

    This activity is intended for general neurologists, neurodegenerative disease specialists, and other healthcare professionals involved in the diagnosis and management of patients with MS.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Apply evolving diagnostic considerations (e.g., oligoclonal bands, autoantibodies, rising biomarkers) in appropriate situations to optimize timely recognition of MS presentations
    • Evaluate key clinical and patient-specific factors that may influence DMT selection to optimally match each patient with particular therapeutic strategies
    • Discuss strategies for the identification and response to subacute disease changes to develop evidence-based management plans for patients
    • Utilize important long-term considerations in MS patient care to tailor clinical decisions commensurate with individual patient needs
  • Accreditation and Credit Designation Statements

    This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient, LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

    PHYSICIAN CREDIT
    Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
    A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

  • Disclaimer

    Disclosure of Relevant Financial Relationships

    To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

    All relevant conflicts of interest have been mitigated prior to the start of the activity.
    None of the planners, reviewers, Efficient LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

    Disclosure of Unlabeled Use/Disclaimer
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Method of Participation
    There are no fees for participating in and receiving credit for this activity. During the period April 25, 2024 through April 25, 2025, participants must: 1) read the learning objectives and faculty disclosures, 2) complete the pre-activity assessment, 3) study the educational activity, 4) complete the posttest by recording the best answer to each question, and 5) complete the evaluation form.

    Media
    Internet

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.

  • Commercial Support

    This activity is supported by an educational grant from Bristol Myers Squibb and Novartis Pharmaceuticals.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule24 May 2024